Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Single-arm, Multicenter Phase I Study of SCH 54031 (Pegylated Interferon Alfa-2b) as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma

Next Previous
X
Search
Trial Profile

An Open-Label, Single-arm, Multicenter Phase I Study of SCH 54031 (Pegylated Interferon Alfa-2b) as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 11 May 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Peginterferon alfa-2b (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Sponsors Merck Sharp & Dohme Corp.

    • Most Recent Events

    • 15 Mar 2017 Status changed from completed to discontinued after 118 weeks from the study start, during the maintenance phase, due to regulatory approval in Japan. .
    • 31 Mar 2016 Status changed from active, no longer recruiting to completed.
    • 16 Feb 2015 According to ClinicalTrials.gov record, protocol amended- patients receive only 6 micrograms/kg SC in the induction phase as compared to 3 or 6 micrograms/kg.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top